Cipla Expands Biosimilars Pipeline Amidst Mixed Financial Performance
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
Mint
Image: Mint
Cipla, a major pharmaceutical company based in Mumbai, is focusing on expanding its biosimilars pipeline, planning to add 1-2 products annually over the next five years. Despite a 54.6% decline in net profit for Q4FY26, the company anticipates strong growth in its core markets, particularly India and the US.
- 01Cipla aims to add 1-2 biosimilars annually over the next 5-6 years.
- 02The company's net profit for Q4FY26 fell by 54.6% year-on-year.
- 03Cipla's One India business grew by 15% year-on-year.
- 04The North America segment generated $155 million in quarterly revenue.
- 05Cipla expects to exceed a $1 billion run rate in the US by FY27.
Advertisement
In-Article Ad
Cipla, headquartered in Mumbai, is strategically investing in the biosimilars market, planning to introduce 1-2 new products each year over the next 5-6 years. CEO Achin Gupta highlighted the company's commitment to advancing its biosimilars pipeline through a joint venture with Kemwell Biopharma. Despite facing challenges, including a 54.6% decline in net profit to ₹554.64 crore for Q4FY26, Cipla's overall revenue for the fiscal year rose by 2% to ₹28,163 crore. The One India business segment, which encompasses branded generics and consumer health, experienced a 15% growth year-on-year. In North America, Cipla reported a quarterly revenue of $155 million, driven by a diverse portfolio. Looking ahead, Gupta expressed confidence in achieving a run rate exceeding $1 billion in the US by the end of FY27, bolstered by a robust product pipeline.
Advertisement
In-Article Ad
Cipla's expansion in the biosimilars market could lead to more affordable medication options for patients in India and the US, potentially improving access to essential drugs.
Advertisement
In-Article Ad
Reader Poll
Do you believe biosimilars will significantly improve access to medications?
Connecting to poll...
More about Cipla
Cipla Reports 55% Drop in Q4 Profit Amid US Market Challenges and Increased R&D Spending
Business Standard • May 13, 2026
Cipla Reports 55% Drop in Q4 Profit, Declares Rs 13 Dividend
The Economic Times • May 13, 2026
Cipla Reports 54.6% Drop in Q4 Profit Amid U.S. Market Challenges
Business Standard • May 13, 2026
Read the original article
Visit the source for the complete story.